Xin Lang Cai Jing·2026-03-04 07:42Core Viewpoint - Kanglong Chemical's stock experienced a slight increase of 0.07% on March 4, with a trading volume of 5.93 billion yuan and a market capitalization of 49.607 billion yuan [1] Group 1: Company Overview - Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. specializes in integrated drug research, development, and production services, covering the entire process from drug discovery to development [2] - The company's main revenue sources include laboratory services (60.43%), CMC (small molecule CDMO) services (21.58%), clinical research services (14.58%), and other services [7] - As of September 30, Kanglong Chemical had 86,500 shareholders, a decrease of 1.62% from the previous period [8] Group 2: Financial Performance - For the period from January to September 2025, Kanglong Chemical achieved a revenue of 10.086 billion yuan, representing a year-on-year growth of 14.38%, while the net profit attributable to shareholders decreased by 19.76% to 1.141 billion yuan [8] - The company has distributed a total of 1.794 billion yuan in dividends since its A-share listing, with 1.007 billion yuan distributed over the past three years [9] Group 3: Market Position and Trends - Kanglong Chemical is positioned within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing, benefiting from trends in innovative drugs, CRO concepts, and artificial intelligence [2][8] - The company is focusing on digital transformation in clinical services, establishing a "Digital Innovation Technology Department" to enhance efficiency through automation and machine learning [3]